The table below shows BIOCRYST PHARMACEUTICALS INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$347.37M
-$52.02M
-$95.14M
-$161.85M
-$142.16M
-$135.11M
Capital expenditure
-
-
-
-
-
-
Investing cash flow
-$13.69M
$52.59M
-$131.50M
-$128.24M
$15.80M
-$6.86M
Dividends paid
-
-
-
-
-
BCRX operating cash flow (10-K history)
BIOCRYST PHARMACEUTICALS INC reported operating cash flow of $347.37M for fiscal year 2025. That is up 767.8% from -$52.02M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$53.44M (FY 2016) to $347.37M. Figures come from the company's audited annual reports as filed with the SEC.
